Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/9/2025 | $23.00 | Buy → Neutral | BofA Securities |
| 5/9/2025 | $52.00 | Strong Buy → Outperform | Raymond James |
| 4/29/2025 | $44.00 | Overweight | Cantor Fitzgerald |
| 12/17/2024 | $36.00 | Buy → Neutral | Goldman |
| 11/21/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 10/25/2024 | $25.00 | Sector Perform | RBC Capital Mkts |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/16/2024 | Outperform | William Blair |
Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00
BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00
Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00
Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the European Renal Association CongressMarketing applications for EMPAVELI are under review with the FDA and EMA WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part o
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;
8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
DEFA14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)